This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
| bigram | frequency |
|---|---|
| respiratory syndrome | 162 |
| middle east | 151 |
| east respiratory | 141 |
| syndrome coronavirus | 141 |
| novel coronavirus | 103 |
| lonicerae japonicae | 76 |
| japonicae flos | 73 |
| growth factor | 72 |
| fibroblast growth | 71 |
| acute respiratory | 49 |
| saudi arabia | 47 |
| cov infection | 37 |
| authentic lonicerae | 35 |
| confirmed covid | 34 |
| flos lonicerae | 33 |
| confirmed cases | 30 |
| avian influenza | 27 |
| severe acute | 26 |
| coronavirus infection | 24 |
| suspected covid | 24 |
| coronavirus disease | 24 |
| nucleic acid | 23 |
| critically ill | 22 |
| public health | 22 |
| respiratory distress | 18 |
| mechanical ventilation | 18 |
| lonicera japonica | 17 |
| world health | 17 |
| south korea | 17 |
| coronavirus pneumonia | 17 |
| health organization | 17 |
| respiratory failure | 17 |
| ill patients | 17 |
| bile acid | 16 |
| spike protein | 16 |
| mitogenic fgfs | 16 |
| chemical fingerprint | 16 |
| respiratory tract | 16 |
| chest ct | 15 |
| health commission | 15 |
| body temperature | 15 |
| clinical characteristics | 15 |
| national health | 15 |
| mers coronavirus | 14 |
| neutralizing antibodies | 14 |
| convalescent plasma | 14 |
| distress syndrome | 14 |
| clinical trials | 14 |
| hubei province | 14 |
| metabolic axis | 14 |
| family cluster | 14 |
| bile acids | 14 |
| fgf axes | 13 |
| doc id | 13 |
| front med | 13 |
| med doi | 13 |
| emergency department | 13 |
| metabolic fgfs | 13 |
| cord uid | 13 |
| human coronavirus | 13 |
| probable covid | 12 |
| severe cases | 12 |
| dromedary camels | 12 |
| fgf metabolic | 12 |
| human transmission | 11 |
| chlorogenic acid | 11 |
| first case | 11 |
| person transmission | 11 |
| infectious diseases | 10 |
| health care | 10 |
| intensive care | 10 |
| may also | 10 |
| japonica thunb | 10 |
| clinical features | 10 |
| adipose tissue | 10 |
| metabolic homeostasis | 10 |
| tested positive | 10 |
| control measures | 10 |
| ecological system | 10 |
| cell proliferation | 10 |
| patients infected | 10 |
| zhejiang province | 10 |
| fgf acts | 10 |
| lopinavir ritonavir | 10 |
| lower respiratory | 10 |
| healthcare workers | 9 |
| cov infections | 9 |
| close contacts | 9 |
| ethics committee | 9 |
| suspected cases | 9 |
| institutional review | 9 |
| disease control | 9 |
| insulin resistance | 9 |
| case definition | 9 |
| research protocol | 9 |
| protocol requiring | 9 |
| relevant institutional | 9 |
| organ failure | 9 |
| bundle pharmacotherapy | 9 |
| respiratory symptoms | 9 |
| requiring approval | 9 |
| cov antibodies | 9 |
| research team | 9 |
| review board | 9 |
| receptor binding | 9 |
| index case | 9 |
| descriptive study | 9 |
| traditional chinese | 9 |
| novel virus | 8 |
| chinese traditional | 8 |
| tumoral calcinosis | 8 |
| commonly used | 8 |
| viral rna | 8 |
| different varieties | 8 |
| patent medicine | 8 |
| glass opacity | 8 |
| united arab | 8 |
| infectious disease | 8 |
| infected pneumonia | 8 |
| hplc fingerprint | 8 |
| seven patients | 8 |
| investigation team | 8 |
| respiratory illness | 8 |
| chinese herbs | 8 |
| severe pneumonia | 8 |
| insulin sensitivity | 8 |
| binding domain | 8 |
| infection control | 8 |
| arab emirates | 8 |
| family case | 8 |
| adipose tissues | 8 |
| metabolic effects | 8 |
| traditional patent | 7 |
| fatty acid | 7 |
| severe respiratory | 7 |
| like protease | 7 |
| component analysis | 7 |
| united states | 7 |
| rhesus macaques | 7 |
| clinical effectiveness | 7 |
| nervous system | 7 |
| among hcp | 7 |
| critical covid | 7 |
| endocrine fgf | 7 |
| incubation period | 7 |
| critical patients | 7 |
| fgf levels | 7 |
| chinese medicine | 7 |
| coexisting conditions | 7 |
| blood pressure | 7 |
| novel human | 7 |
| acquired pneumonia | 7 |
| new coronavirus | 7 |
| mouse model | 7 |
| energy expenditure | 7 |
| multiple organ | 7 |
| mitogenic fgf | 7 |
| weight loss | 7 |
| producing areas | 7 |
| fat diet | 7 |
| metabolic axes | 7 |
| fatty liver | 7 |
| systematic review | 7 |
| upper respiratory | 7 |
| clinical symptoms | 7 |
| kl klb | 7 |
| serologic testing | 7 |
| ct scan | 7 |
| current situation | 7 |
| invasive mechanical | 6 |
| arabian peninsula | 6 |
| coronavirus infections | 6 |
| ncov outbreak | 6 |
| medical staff | 6 |
| fgf expression | 6 |
| therapeutic options | 6 |
| close contact | 6 |
| oxygen therapy | 6 |
| coronavirus middle | 6 |
| health emergency | 6 |
| ncov infection | 6 |
| old male | 6 |
| hospitalized patients | 6 |
| severe patients | 6 |
| pneumonia outbreak | 6 |
| quality control | 6 |
| cov cases | 6 |
| family members | 6 |
| pharmacological effects | 6 |
| closely related | 6 |
| skeletal muscle | 6 |
| household contacts | 6 |
| diabetes mellitus | 6 |
| germplasm resources | 6 |
| familial cluster | 6 |
| respiratory support | 6 |
| metabolic fgf | 6 |
| global health | 6 |
| epithelial cells | 6 |
| cell count | 6 |
| genetic diversity | 6 |
| coronavirus replication | 6 |
| secondary cases | 6 |
| tested negative | 6 |
| results showed | 6 |
| authentic product | 6 |
| cell lines | 6 |
| dry cough | 5 |
| bat origin | 5 |
| highly suspected | 5 |
| transmission dynamics | 5 |
| china novel | 5 |
| acid testing | 5 |
| familial tumoral | 5 |
| structural elements | 5 |
| human infections | 5 |
| antiviral treatment | 5 |
| fatality rate | 5 |
| transgenic mice | 5 |
| population growth | 5 |
| acid test | 5 |
| signal axes | 5 |
| travel history | 5 |
| serum fgf | 5 |
| pediatric patients | 5 |
| risk assessment | 5 |
| moderate patients | 5 |
| hepatic fgf | 5 |
| fgf promotes | 5 |
| including deaths | 5 |
| chain reaction | 5 |
| membrane fusion | 5 |
| glucose uptake | 5 |
| widely used | 5 |
| ct images | 5 |
| hong kong | 5 |
| observational study | 5 |
| organ dysfunction | 5 |
| nasopharyngeal swab | 5 |
| pharmacological fgf | 5 |
| spike glycoprotein | 5 |
| care unit | 5 |
| clinical manifestations | 5 |
| emergency committee | 5 |
| western medicine | 5 |
| islet hyperplasia | 5 |
| patients admitted | 5 |
| parathyroid hormone | 5 |
| converting enzyme | 5 |
| fgf family | 5 |
| virus entry | 5 |
| seven cases | 5 |
| computed tomography | 5 |
| symptoms resolved | 5 |
| infectious virus | 5 |
| fgf may | 5 |
| fgf axis | 5 |
| klb complex | 5 |
| coronavirus investigating | 5 |
| early phase | 5 |
| broad spectrum | 5 |
| cd cd | 5 |
| abdominal pain | 5 |
| interorgan crosstalk | 5 |
| seven critically | 5 |
| noxious substances | 5 |
| tissue remodeling | 5 |
| viral infections | 5 |
| mortality rate | 5 |
| arabia middle | 5 |
| positive results | 5 |
| polymerase chain | 5 |
| review article | 5 |
| risk factors | 5 |
| white blood | 5 |
| promote cell | 5 |
| care medicine | 5 |
| deficient mice | 5 |
| ground glass | 5 |
| fever clinic | 5 |
| infected patients | 5 |
| comparative study | 5 |
| critical ppe | 4 |
| metabolic rate | 4 |
| within days | 4 |
| type diabetes | 4 |
| first patient | 4 |
| pneumonia caused | 4 |
| chest computed | 4 |
| healthcare personnel | 4 |
| binding protein | 4 |
| endocrine fgfs | 4 |
| healthcare settings | 4 |
| seafood wholesale | 4 |
| heparan sulfate | 4 |
| cardiac hypertrophy | 4 |
| median time | 4 |
| human infection | 4 |
| wholesale market | 4 |
| active component | 4 |
| chinese medical | 4 |
| common marmoset | 4 |
| nk cells | 4 |
| pneumonia associated | 4 |
| stress response | 4 |
| metabolic tissues | 4 |
| dipeptidyl peptidase | 4 |
| heart failure | 4 |
| local governments | 4 |
| coronavirus neutralizing | 4 |
| fingerprint chromatogram | 4 |
| therapeutic strategies | 4 |
| high levels | 4 |
| genome sequence | 4 |
| test results | 4 |
| text database | 4 |
| plasma transfusion | 4 |
| bone marrow | 4 |
| huanan seafood | 4 |
| brown adipose | 4 |
| informed consent | 4 |
| blood cell | 4 |
| neutralizing antibody | 4 |
| important factor | 4 |
| creatine kinase | 4 |
| first confirmed | 4 |
| clinical trial | 4 |
| gas chromatography | 4 |
| another study | 4 |
| clinical specimens | 4 |
| cell entry | 4 |
| chronic kidney | 4 |
| specific igm | 4 |
| kidney disease | 4 |
| electron probe | 4 |
| clinical practice | 4 |
| influenza virus | 4 |
| case report | 4 |
| intravascular coagulation | 4 |
| thereby leading | 4 |
| oxidative stress | 4 |
| authentic herbs | 4 |
| emerging novel | 4 |
| acinar cell | 4 |
| severe covid | 4 |
| morphological characteristics | 4 |
| association committee | 4 |
| cov replication | 4 |
| indicating person | 4 |
| epidemic prevention | 4 |
| three times | 4 |
| extracellular matrix | 4 |
| coronavirus outbreak | 4 |
| healthcare facilities | 4 |
| two patients | 4 |
| early transmission | 4 |
| swab specimen | 4 |
| live poultry | 4 |
| immune system | 4 |
| three cases | 4 |
| kidney injury | 4 |
| materia medica | 4 |
| inflammatory response | 4 |
| acute kidney | 4 |
| immune response | 4 |
| liver disease | 4 |
| infect humans | 4 |
| one case | 4 |
| acid oxidation | 4 |
| positive rate | 4 |
| monoclonal antibody | 4 |
| spring festival | 4 |
| functional receptor | 4 |
| liquid chromatography | 4 |
| autocrine paracrine | 4 |
| viral load | 4 |
| cohort study | 4 |
| coronavirus emc | 4 |
| literature update | 4 |
| care facilities | 4 |
| creative commons | 4 |
| respiratory droplets | 4 |
| phosphate wasting | 4 |
| interquartile range | 4 |
| international concern | 4 |
| amino acid | 4 |
| inflammatory damage | 4 |
| gastrointestinal symptoms | 4 |
| contact investigation | 4 |
| cleavage site | 4 |
| disseminated intravascular | 4 |
| chinese materia | 4 |
| cov outbreak | 4 |
| studies showed | 4 |
| coronavirus indicating | 4 |
| oxygen saturation | 4 |
| coronavirus spike | 4 |
| mg day | 4 |
| probable bat | 4 |
| protective equipment | 4 |
| factor protects | 4 |
| clinical course | 4 |
| outbreak associated | 4 |
| animal model | 4 |
| time reverse | 4 |
| journal full | 4 |
| improves outcome | 4 |
| viral pneumonia | 4 |
| median incubation | 4 |
| reproduction number | 4 |
| tissues organs | 4 |
| noninvasive ventilation | 4 |
| geoauthentic lonicerae | 3 |
| respiratory disease | 3 |
| positive cases | 3 |
| epidemiological data | 3 |
| cytokine storms | 3 |
| fgf gene | 3 |
| cases developed | 3 |
| multiple tissues | 3 |
| coronavirus genomes | 3 |
| critical care | 3 |
| regulatory element | 3 |
| adult patients | 3 |
| coronavirus study | 3 |
| matrix heparan | 3 |
| hyaline membrane | 3 |
| human cases | 3 |
| red long | 3 |
| missed diagnosis | 3 |
| care workers | 3 |
| highly pathogenic | 3 |
| ncov case | 3 |
| cell culture | 3 |
| hr domains | 3 |
| thereby reducing | 3 |
| clinical studies | 3 |
| rna polymerase | 3 |
| metabolic syndrome | 3 |
| general dr | 3 |
| spectrum antiviral | 3 |
| first laboratory | 3 |
| wound healing | 3 |
| new virus | 3 |
| jinyebaidu granules | 3 |
| phylogenetic analysis | 3 |
| case fatality | 3 |
| total number | 3 |
| cell membrane | 3 |
| two consecutive | 3 |
| chinese center | 3 |
| reactive protein | 3 |
| epidemic situation | 3 |
| primate model | 3 |
| three years | 3 |
| confirmed patients | 3 |
| normal levels | 3 |
| requiring mv | 3 |
| chinese mainland | 3 |
| multiple organs | 3 |
| unprecedented responses | 3 |
| autosomal recessive | 3 |
| analysis showed | 3 |
| respiratory infections | 3 |
| influenza viruses | 3 |
| neutralization assay | 3 |
| mice lacking | 3 |
| secondary transmission | 3 |
| second chest | 3 |
| three patients | 3 |
| peripheral tissues | 3 |
| descriptive genomic | 3 |
| resolution liquid | 3 |
| chinese government | 3 |
| viral replication | 3 |
| also used | 3 |
| fatty acids | 3 |
| studies mainly | 3 |
| mice developed | 3 |
| standard chemical | 3 |
| systemic metabolic | 3 |
| spectrum antivirals | 3 |
| highly similar | 3 |
| henan province | 3 |
| lonicera macrathodes | 3 |
| lymphocyte count | 3 |
| health authorities | 3 |
| patients presented | 3 |
| including fgf | 3 |
| death caused | 3 |
| emergency response | 3 |
| macrathodes hands | 3 |
| medical professionals | 3 |
| weight heparin | 3 |
| respiratory specimens | 3 |
| sugar intake | 3 |
| also found | 3 |
| energy metabolism | 3 |
| phase trial | 3 |
| pharyngeal swabs | 3 |
| cases may | 3 |
| one study | 3 |
| high mortality | 3 |
| herbal medicine | 3 |
| patients receiving | 3 |
| underlying comorbidities | 3 |
| product areas | 3 |
| grand dictionary | 3 |
| may june | 3 |
| moderate covid | 3 |
| supplementary material | 3 |
| north america | 3 |
| pleural effusion | 3 |
| critical roles | 3 |
| type ii | 3 |
| common ward | 3 |
| medica grand | 3 |
| symptom onset | 3 |
| polymorphism analysis | 3 |
| human fibroblast | 3 |
| coronavirus receptor | 3 |
| washington state | 3 |
| case investigation | 3 |
| extracorporeal membrane | 3 |
| muscle wasting | 3 |
| controlled trials | 3 |
| cause human | 3 |
| patients received | 3 |
| hands mazz | 3 |
| early noninvasive | 3 |
| acid biosynthesis | 3 |
| shandong province | 3 |
| since december | 3 |
| authentic producing | 3 |
| medical institutions | 3 |
| disease progressed | 3 |
| personal protective | 3 |
| induces fgf | 3 |
| length polymorphism | 3 |
| significantly higher | 3 |
| specific antiviral | 3 |
| municipal government | 3 |
| interstitial pneumonia | 3 |
| tract samples | 3 |
| nonhuman primate | 3 |
| pcr assays | 3 |
| restriction fragment | 3 |
| metabolic pathways | 3 |
| recently emerged | 3 |
| membrane oxygenation | 3 |
| consensus statement | 3 |
| china cdc | 3 |
| virus outbreak | 3 |
| septic shock | 3 |
| postponing resumption | 3 |
| nasal cannula | 3 |
| increased levels | 3 |
| standardized data | 3 |
| target tissues | 3 |
| metabolic diseases | 3 |
| metabolic regulator | 3 |
| patients showed | 3 |
| systemic mineral | 3 |
| took place | 3 |
| mineral balance | 3 |
| immune responses | 3 |
| anal swabs | 3 |
| complications tend | 3 |
| renal failure | 3 |
| binding affinity | 3 |
| interim guidance | 3 |
| sequential ventilation | 3 |
| spread mainly | 3 |
| white adipose | 3 |
| rate increased | 3 |
| cytokine storm | 3 |
| glucocorticoid treatment | 3 |
| human angiotensin | 3 |
| hospital outbreak | 3 |
| abattoir workers | 3 |
| scavenging capacities | 3 |
| sterol regulatory | 3 |
| fragment length | 3 |
| second case | 3 |
| dna synthesis | 3 |
| angiotensin ii | 3 |
| infected cells | 3 |
| within km | 3 |
| emerging middle | 3 |
| sequential noninvasive | 3 |
| chest tightness | 3 |
| plasma therapy | 3 |
| health measures | 3 |
| laboratory confirmation | 3 |
| electron microscopy | 3 |
| trueborn flos | 3 |
| fat content | 3 |
| different regions | 3 |
| showed diffuse | 3 |
| human disease | 3 |
| signaling pathway | 3 |
| pharmacotherapy regimen | 3 |
| chest imaging | 3 |
| least days | 3 |
| respiratory samples | 3 |
| fgf signal | 3 |
| clinical signs | 3 |
| jiangsu province | 3 |
| chronic hepatitis | 3 |
| patients presenting | 3 |
| medical association | 3 |
| clinical conditions | 3 |
| emerging infectious | 3 |
| unknown origin | 3 |
| novel avian | 3 |
| shandong provinces | 3 |
| green arrow | 3 |
| sporadic cases | 3 |
| genomic study | 3 |
| hospital admission | 3 |
| confirmed case | 3 |
| healthcare worker | 3 |
| nucleoside analogs | 3 |
| full genome | 3 |
| derived fgf | 3 |
| sampling interval | 3 |
| stress damage | 3 |
| fgf regulates | 3 |
| ncov test | 3 |
| membrane formation | 3 |
| failure requiring | 3 |
| nonstructural proteins | 3 |
| therapeutic effects | 3 |
| bone health | 3 |
| muscle mass | 3 |
| patient presented | 3 |
| genomic characterisation | 3 |
| china clinical | 3 |
| hypophosphatemic rickets | 3 |
| golgi apparatus | 3 |
| mers patients | 3 |
| human coronaviruses | 3 |
| pathogenic coronavirus | 3 |
| study group | 3 |
| gum inflammation | 3 |
| rapid resolution | 3 |
| bat coronaviruses | 3 |
| one patient | 3 |
| blood urea | 3 |
| worst hit | 3 |
| virus origins | 3 |
| mycophenolic acid | 3 |
| dpp receptor | 3 |
| tissue damage | 3 |
| patient died | 3 |
| measures taken | 3 |
| previously unknown | 3 |
| xiaokun li | 3 |
| mitogenic axis | 3 |
| nonalcoholic steatohepatitis | 3 |
| certified flos | 3 |
| hajj pilgrims | 3 |
| commons licence | 3 |
| two cases | 3 |
| mild upper | 3 |
| camel sera | 3 |
| monoclonal antibodies | 3 |
| patchy shadows | 3 |
| recently traveled | 3 |
| interim case | 3 |
| hepatocellular carcinoma | 3 |
| missense mutation | 3 |
| showed multiple | 3 |
| frequently detected | 3 |
| innate immune | 3 |
| disease progression | 3 |
| critical cases | 3 |
| fgfs appear | 3 |
| respiratory rate | 3 |
| serological study | 3 |
| metabolic derangements | 3 |
| increased serum | 3 |
| processing methods | 3 |
| used method | 3 |
| took care | 3 |
| high affinity | 3 |
| scan showed | 3 |
| cov transmission | 3 |
| prolonged fasting | 3 |
| genome sequences | 3 |
| obese mice | 3 |
| fusion core | 3 |
| fungal infection | 3 |
| urea nitrogen | 3 |
| three cultivars | 3 |
| quality evaluation | 3 |
| successful management | 3 |
| secondary infections | 3 |
| diabetic cardiomyopathy | 3 |
| affected countries | 3 |
| intravenous injection | 3 |
| wide range | 3 |
| reported among | 3 |
| ihr emergency | 3 |
| reading frames | 3 |
| pathological findings | 3 |
| invasive ventilation | 3 |
| human influenza | 3 |
| early stage | 3 |
| studies discussed | 3 |
| mildly symptomatic | 3 |
| inflammatory infiltration | 3 |
| within two | 3 |
| retrospective study | 3 |
| two studies | 3 |
| contact history | 3 |
| pulmonary edema | 3 |
| bat coronavirus | 3 |
| blood donors | 3 |
| medical team | 3 |
| recent outbreak | 3 |
| medical records | 3 |
| subunit vaccine | 3 |
| animal source | 3 |
| laboratory testing | 3 |
| confirmed based | 2 |
| intracellular kinase | 2 |
| phase iii | 2 |
| unique structural | 2 |
| taphozous perforatus | 2 |
| viral infectivity | 2 |
| exert therapeutic | 2 |
| lactate dehydrogenase | 2 |
| first honeysuckle | 2 |
| higher quality | 2 |
| climate factors | 2 |
| disease transmission | 2 |
| treated using | 2 |
| two months | 2 |
| plucking time | 2 |
| tongji medical | 2 |
| signal axis | 2 |
| characteristic cytopathic | 2 |
| genomic characterization | 2 |
| body weight | 2 |
| life expectancy | 2 |
| fgf signaling | 2 |
| production areas | 2 |
| china genomic | 2 |
| literature database | 2 |
| rapidly spread | 2 |
| nonalcoholic fatty | 2 |
| prone positioning | 2 |
| following criteria | 2 |
| congestive heart | 2 |
| first covid | 2 |
| cov spike | 2 |
| thereby preventing | 2 |
| epidemiology team | 2 |
| coronavirus infected | 2 |
| attenuate inflammation | 2 |
| financial support | 2 |
| professional development | 2 |
| epo levels | 2 |
| newly emerged | 2 |
| two samples | 2 |
| associated outbreak | 2 |
| neutralizing monoclonal | 2 |
| cov patients | 2 |
| fusion peptide | 2 |
| metabolic disorders | 2 |
| pathological changes | 2 |
| viral entry | 2 |
| activities driven | 2 |
| medical center | 2 |
| increased risks | 2 |
| often used | 2 |
| biological effects | 2 |
| rna genome | 2 |
| controlled trial | 2 |
| igg antibodies | 2 |
| avian populations | 2 |
| multiple shedding | 2 |
| latest guidelines | 2 |
| avian coronaviruses | 2 |
| mental status | 2 |
| mass index | 2 |
| coronavirus originating | 2 |
| seasonal influenza | 2 |
| huazhong university | 2 |
| outbreak occurred | 2 |
| antiviral treatments | 2 |
| rna virus | 2 |
| pathway fibroblast | 2 |
| paracrine mitogenic | 2 |
| different biological | 2 |
| final exam | 2 |
| three members | 2 |
| ongoing clinical | 2 |
| ribavirin improves | 2 |
| cumulative number | 2 |
| lessons learned | 2 |
| highly sensitive | 2 |
| adjusted estimation | 2 |
| rheumatoid arthritis | 2 |
| among pilgrims | 2 |
| new cov | 2 |
| specific treatment | 2 |
| virus isolated | 2 |
| randomized clinical | 2 |
| oral oseltamivir | 2 |
| gradually decreased | 2 |
| coronavirus epidemic | 2 |
| dependent mechanism | 2 |
| antipyretic effect | 2 |
| cases included | 2 |
| factor action | 2 |
| lung disease | 2 |
| rrna gene | 2 |
| study middle | 2 |
| highly contagious | 2 |
| samples collected | 2 |
| renal proximal | 2 |
| deficient diet | 2 |
| protein nanoparticles | 2 |
| clinical management | 2 |
| proliferatoractivated receptor | 2 |
| acute renal | 2 |
| axis drives | 2 |
| healthy individuals | 2 |
| shedding routes | 2 |
| genuine producing | 2 |
| effectively inhibit | 2 |
| gene sequence | 2 |
| sars coronavirus | 2 |
| metabolic perturbations | 2 |
| tradit herbal | 2 |
| glucose homeostasis | 2 |
| infected individuals | 2 |
| laboratory findings | 2 |
| large outbreaks | 2 |
| imaging features | 2 |
| new bile | 2 |
| ng ml | 2 |
| medicine research | 2 |
| treat middle | 2 |
| vascular calcification | 2 |
| open reading | 2 |
| medical education | 2 |
| will reduce | 2 |
| severe illness | 2 |
| still unclear | 2 |
| coronavirus diseases | 2 |
| scientific journal | 2 |
| ketogenic diet | 2 |
| orphan receptor | 2 |
| lung changes | 2 |
| peroxisome proliferator | 2 |
| nosocomial outbreaks | 2 |
| adverse effects | 2 |
| fibrous dysplasia | 2 |
| confirmatory testing | 2 |
| dominant hypophosphatemic | 2 |
| autosomal dominant | 2 |
| exocrine pancreas | 2 |
| february except | 2 |
| high prevalence | 2 |
| confirmed human | 2 |
| early symptoms | 2 |
| also described | 2 |
| coronavirus isolated | 2 |
| increased epo | 2 |
| sequence divergence | 2 |
| trained staff | 2 |
| reverse transcription | 2 |
| flow nasal | 2 |
| aspergillus flavus | 2 |
| sympathetic nervous | 2 |
| infiltrating shadows | 2 |
| guidelines issued | 2 |
| comprehensive review | 2 |
| sustained hypoxia | 2 |
| serological investigation | 2 |
| sichuan province | 2 |
| extraction table | 2 |
| cell injury | 2 |
| several major | 2 |
| side effects | 2 |
| clinical manifestation | 2 |
| cause respiratory | 2 |
| alveolar epithelial | 2 |
| mers outbreak | 2 |
| kz i | 2 |
| embryonic development | 2 |
| call hereafter | 2 |
| aspartate aminotransferase | 2 |
| cases suggestive | 2 |
| hcp working | 2 |
| day survival | 2 |
| pneumonia clinical | 2 |
| symptoms disappeared | 2 |
| paracrine fgf | 2 |
| clinical application | 2 |
| radiological characteristics | 2 |
| laboratory results | 2 |
| syncytial cells | 2 |
| erasmus medical | 2 |
| controlled phase | 2 |
| mdck cells | 2 |
| volatile oil | 2 |
| expressing hdpp | 2 |
| like coronavirus | 2 |
| median mv | 2 |
| producing area | 2 |
| nosocomial transmission | 2 |
| related orphan | 2 |
| biliary cholangitis | 2 |
| cannula oxygen | 2 |
| governance perspective | 2 |
| among confirmed | 2 |
| associated outbreaks | 2 |
| functional divergence | 2 |
| calcium reabsorption | 2 |
| acute pneumonia | 2 |
| remains low | 2 |
| control mechanism | 2 |
| metabolic health | 2 |
| lung injury | 2 |
| mild clinical | 2 |
| eventually died | 2 |
| inflammatory mediators | 2 |
| decreased viral | 2 |
| slaughterhouse workers | 2 |
| alanine aminotransferase | 2 |
| coronavirus antibodies | 2 |
| triad complex | 2 |
| patients manifested | 2 |
| presented fever | 2 |
| hospital contacts | 2 |
| tract symptoms | 2 |
| integrated stress | 2 |
| main producing | 2 |
| renal dysfunction | 2 |
| six days | 2 |
| also discussed | 2 |
| coronavirus causing | 2 |
| evaluating clinical | 2 |
| causes familial | 2 |
| underlying disease | 2 |
| min zhou | 2 |
| ebola virus | 2 |
| study showed | 2 |
| serum levels | 2 |
| previous epidemics | 2 |
| studies analyzed | 2 |
| bactrian camels | 2 |
| heavy mental | 2 |
| different species | 2 |
| whole country | 2 |
| processing method | 2 |
| common fgf | 2 |
| first cluster | 2 |
| treatment options | 2 |
| acid content | 2 |
| unknown cause | 2 |
| bilateral patchy | 2 |
| fatal outcome | 2 |
| method used | 2 |
| attenuate stress | 2 |
| host cells | 2 |
| case series | 2 |
| new type | 2 |
| block virus | 2 |
| study reports | 2 |
| pcr tests | 2 |
| associated pneumonia | 2 |
| involved lung | 2 |
| bowel function | 2 |
| cholesterol efflux | 2 |
| saijuan chen | 2 |
| investigation revealed | 2 |
| high fat | 2 |
| severe middle | 2 |
| chinese scientific | 2 |
| acid sequence | 2 |
| old female | 2 |
| protective role | 2 |
| protein microarray | 2 |
| obesogenic diet | 2 |
| response epidemiology | 2 |
| hospital outbreaks | 2 |
| whereas igg | 2 |
| oral ulcer | 2 |
| intravenous infusion | 2 |
| patients underwent | 2 |
| drive effects | 2 |
| family contacts | 2 |
| highest quality | 2 |
| another case | 2 |
| first reported | 2 |
| poultry market | 2 |
| pancreatic fgf | 2 |
| tedros adhanom | 2 |
| em structure | 2 |
| will win | 2 |
| lymphoid infiltration | 2 |
| sense rna | 2 |
| fgf drive | 2 |
| metabolic roles | 2 |
| coronavirus epidemiological | 2 |
| ncov infected | 2 |
| glucose reabsorption | 2 |
| actual number | 2 |
| effective measures | 2 |
| treatment protocol | 2 |
| quality assessment | 2 |
| two weeks | 2 |
| days later | 2 |
| many cases | 2 |
| medical college | 2 |
| team also | 2 |
| virus spread | 2 |
| health emergencies | 2 |
| acinetobacter baumannii | 2 |
| chest radiograph | 2 |
| renal phosphate | 2 |
| signaling pathways | 2 |
| prone position | 2 |
| viral polyproteins | 2 |
| studies regarding | 2 |
| transmission patterns | 2 |
| accessory proteins | 2 |
| hospital starting | 2 |
| trial version | 2 |
| hcp infection | 2 |
| hospital patients | 2 |
| day methylprednisolone | 2 |
| previous experience | 2 |
| early sequential | 2 |
| gel electrophoresis | 2 |
| studies reported | 2 |
| unprecedented efforts | 2 |
| take oral | 2 |
| aerosol inhalation | 2 |
| brown fat | 2 |
| factor fibroblast | 2 |
| initially named | 2 |
| cord injury | 2 |
| sample nucleic | 2 |
| pipistrellus bat | 2 |
| acquired phosphate | 2 |
| many unanswered | 2 |
| scans showed | 2 |
| fgf subfamily | 2 |
| symptomatic cases | 2 |
| infected animals | 2 |
| gene source | 2 |
| mottled skin | 2 |
| core body | 2 |
| sequence repeat | 2 |
| spread around | 2 |
| hubei medical | 2 |
| multinucleated syncytial | 2 |
| expert group | 2 |
| temporal interorgan | 2 |
| emerged novel | 2 |
| supportive treatment | 2 |
| active fgf | 2 |
| epidemiologic investigation | 2 |
| first identified | 2 |
| infrared spectrum | 2 |
| camels middle | 2 |
| subcutaneous injection | 2 |
| treating influenza | 2 |
| cov case | 2 |
| capital city | 2 |
| inflection point | 2 |
| also occurred | 2 |
| extrahepatic cholestasis | 2 |
| tracheal intubation | 2 |
| neuraminidase inhibitors | 2 |
| current knowledge | 2 |
| active components | 2 |
| proximal tubule | 2 |
| pilgrims returning | 2 |
| system support | 2 |
| epidemic spread | 2 |
| authentic production | 2 |
| epidemiological assessment | 2 |
| atypical pneumonia | 2 |
| sore throat | 2 |
| glucose metabolism | 2 |
| family clusters | 2 |
| rate among | 2 |
| antiviral therapy | 2 |
| early detection | 2 |
| viral infection | 2 |
| lymphocyte counts | 2 |
| hospital affiliated | 2 |
| specific drugs | 2 |
| important lessons | 2 |
| retrospective cohort | 2 |
| liver injury | 2 |
| pp ab | 2 |
| rapd fingerprint | 2 |
| date palm | 2 |
| metabolic regulation | 2 |
| shandong trueborn | 2 |
| retinoic acid | 2 |
| initial symptoms | 2 |
| causative factor | 2 |
| cancer types | 2 |
| abnormal coagulation | 2 |
| associated mers | 2 |
| fgf increases | 2 |
| malayan pangolins | 2 |
| long time | 2 |
| hepatic steatosis | 2 |
| state council | 2 |
| serum igm | 2 |
| digestive tract | 2 |
| sequence homology | 2 |
| important role | 2 |
| brush border | 2 |
| human middle | 2 |
| functional specifications | 2 |
| urban areas | 2 |
| postexposure efficacy | 2 |
| distal tubules | 2 |
| global public | 2 |
| online version | 2 |
| xiaokun title | 2 |
| outside wuhan | 2 |
| clinical data | 2 |
| serum antibodies | 2 |
| ectopic expression | 2 |
| adult family | 2 |
| mitogenic members | 2 |
| subsequent clinical | 2 |
| obese patients | 2 |
| developed symptoms | 2 |
| fgf protects | 2 |
| clinical presentation | 2 |
| thereby alleviating | 2 |
| cell types | 2 |
| treatment strategies | 2 |
| presented coagulation | 2 |
| southern china | 2 |
| acute blood | 2 |
| er stress | 2 |
| recessive familial | 2 |
| last three | 2 |
| laboratory tests | 2 |
| vein thrombosis | 2 |
| identified among | 2 |
| oral jinyebaidu | 2 |
| spectrum antibiotics | 2 |
| fatal case | 2 |
| herbal drugs | 2 |
| revised case | 2 |
| cell membranes | 2 |
| active role | 2 |
| recent years | 2 |
| elevated il | 2 |
| cardiac injury | 2 |
| pulmonary ventilation | 2 |
| antipyretic herbal | 2 |
| symptoms exist | 2 |
| subsequent activation | 2 |
| transcriptional control | 2 |
| metabolic states | 2 |
| ncov spike | 2 |
| cell tissue | 2 |
| wenzhou people | 2 |
| diet induced | 2 |
| prefusion conformation | 2 |
| clear evidence | 2 |
| less susceptible | 2 |
| chinese spring | 2 |
| mice overexpressing | 2 |
| radiograph showed | 2 |
| inhibits mers | 2 |
| target cells | 2 |
| central nervous | 2 |
| crosstalk network | 2 |
| sclerosing cholangitis | 2 |
| research shows | 2 |
| diagnostic criteria | 2 |
| six months | 2 |
| cells exhibited | 2 |
| study conducted | 2 |
| available data | 2 |
| phosphate transport | 2 |
| clinical laboratory | 2 |
| hcp infections | 2 |
| radiological findings | 2 |
| air bronchogram | 2 |
| geoauthentic herbs | 2 |
| patient infected | 2 |
| significantly reduced | 2 |
| differentiate mers | 2 |
| distal renal | 2 |
| jkjyh cs | 2 |
| heptad repeat | 2 |
| tyrosine kinases | 2 |
| virological studies | 2 |
| french pilgrims | 2 |
| whole world | 2 |
| per day | 2 |
| therapeutic agents | 2 |
| smooth muscle | 2 |
| etiologic analysis | 2 |
| total ash | 2 |
| public places | 2 |
| dynamic monitoring | 2 |
| core structure | 2 |
| complex interorgan | 2 |
| case reporting | 2 |
| poor response | 2 |
| tract disease | 2 |
| back memories | 2 |
| coronavirus treatment | 2 |
| related coronaviruses | 2 |
| emerging coronaviruses | 2 |
| determined via | 2 |
| specific rrt | 2 |
| water intake | 2 |
| liver fat | 2 |
| report described | 2 |
| unless indicated | 2 |
| utmost importance | 2 |
| free fatty | 2 |
| mesangial cells | 2 |
| zhejiang strain | 2 |
| rhesus macaque | 2 |
| key technology | 2 |
| host cell | 2 |
| pcr detection | 2 |
| cd nk | 2 |
| viral titers | 2 |
| fgf level | 2 |
| right lower | 2 |
| negative respiratory | 2 |
| consolidation shadow | 2 |
| respiratory infection | 2 |
| health consequences | 2 |
| like ancestor | 2 |
| chin tradit | 2 |
| human conjunctivitis | 2 |
| gene spacer | 2 |
| oral liquid | 2 |
| db db | 2 |
| play critical | 2 |
| early january | 2 |
| ancestor molecule | 2 |
| two decades | 2 |
| product area | 2 |
| new strain | 2 |
| ha gene | 2 |
| fat percentage | 2 |
| conserved core | 2 |
| expressway entrances | 2 |
| presented mild | 2 |
| higher blood | 2 |
| exclusion criteria | 2 |
| effective prevention | 2 |
| proximal tubules | 2 |
| four patients | 2 |
| first manifestation | 2 |
| honeysuckle peak | 2 |
| body mass | 2 |
| multiple introduction | 2 |
| mice fibroblast | 2 |
| later stage | 2 |
| treating mers | 2 |
| db mice | 2 |
| days post | 2 |
| fgfs drive | 2 |
| mv durations | 2 |
| probe method | 2 |
| associated comorbidities | 2 |
| antimicrobial agents | 2 |
| positive airway | 2 |
| study ribavirin | 2 |
| cases increased | 2 |
| ncov pneumonia | 2 |
| fgf drives | 2 |
| blood loss | 2 |
| military support | 2 |
| factor regulates | 2 |
| heat generation | 2 |
| infection prevention | 2 |
| circadian behavior | 2 |
| free radicals | 2 |
| histological examination | 2 |
| fgf directly | 2 |
| cell survival | 2 |
| acid diarrhea | 2 |
| imported cases | 2 |
| ancestor fgf | 2 |
| direct proliferation | 2 |
| feb ei | 2 |
| icu groups | 2 |
| also common | 2 |
| ii alveolar | 2 |
| peak bbs | 2 |
| cov infected | 2 |
| lipid droplet | 2 |
| early stages | 2 |
| also important | 2 |
| preliminary epidemiological | 2 |
| infections clinical | 2 |
| two different | 2 |
| white cell | 2 |
| using nasopharyngeal | 2 |
| chinese strains | 2 |
| activated receptor | 2 |
| chloroquine effectively | 2 |
| apparent heterogeneity | 2 |
| health community | 2 |
| transcriptase polymerase | 2 |
| vaccinia virus | 2 |
| general population | 2 |
| three days | 2 |
| palm orchard | 2 |
| obvious adverse | 2 |
| medicine shuanghuanglian | 2 |
| fatty degeneration | 2 |
| virus ankara | 2 |
| government convened | 2 |
| nadph oxidase | 2 |
| first step | 2 |
| saudi ministry | 2 |
| starvation hormone | 2 |
| early prone | 2 |
| soil types | 2 |
| immune cells | 2 |
| alveolar edema | 2 |
| least two | 2 |
| candida albicans | 2 |
| endocrine mode | 2 |
| specific igg | 2 |
| common symptoms | 2 |
| ncov transmission | 2 |
| cov investigation | 2 |
| five studies | 2 |
| solid nodules | 2 |
| mainly discussing | 2 |
| organ function | 2 |
| interferon therapy | 2 |
| without obvious | 2 |
| probable case | 2 |
| lipid catabolism | 2 |
| acid synthesis | 2 |
| wuhan city | 2 |
| oxygen species | 2 |
| large healthcare | 2 |
| reported outside | 2 |
| wenzhou municipal | 2 |
| include fever | 2 |
| treatment regimen | 2 |
| supportive care | 2 |
| camel shepherds | 2 |
| antibody detection | 2 |
| god mountain | 2 |
| renal tubular | 2 |
| increases energy | 2 |
| antibody response | 2 |
| patients lived | 2 |
| scientific basis | 2 |
| high fatality | 2 |
| increased lactate | 2 |
| airway pressure | 2 |
| eastern province | 2 |
| center study | 2 |
| common ancestor | 2 |
| mice expressing | 2 |
| treat covid | 2 |
| renal tubules | 2 |
| face masks | 2 |
| primary biliary | 2 |
| asymptomatic infection | 2 |
| next day | 2 |
| system environment | 2 |
| induced osteomalacia | 2 |
| epidemiological characteristics | 2 |
| circulating levels | 2 |
| acute cardiac | 2 |
| lower total | 2 |
| novel strain | 2 |
| exposure history | 2 |
| virus initially | 2 |
| kl complex | 2 |
| human betacoronavirus | 2 |
| fgf fgf | 2 |
| jian xiao | 2 |
| induced metabolic | 2 |
| pharyngeal swab | 2 |
| fungal infections | 2 |
| respiratory sample | 2 |
| asymptomatic covid | 2 |
| pcr testing | 2 |
| arabia showed | 2 |
| tocilizumab needs | 2 |
| cells ruptured | 2 |
| lonicerae comparative | 2 |
| retrospectively analyzed | 2 |
| international health | 2 |
| chinese central | 2 |
| shuanghuanglian oral | 2 |
| patchy ground | 2 |
| since february | 2 |
| fgf maintains | 2 |
| dao wen | 2 |
| active calcitriol | 2 |
| dysfunction via | 2 |
| growth factors | 2 |
| infection risks | 2 |
| transgenic mouse | 2 |
| clinical description | 2 |
| promising antivirals | 2 |
| oral consent | 2 |
| cytopathic effect | 2 |
| regulatory activities | 2 |
| nerve activity | 2 |
| transintestinal flux | 2 |
| serological testing | 2 |
| metabolic state | 2 |
| spinal cord | 2 |
| ventricular hypertrophy | 2 |
| viral core | 2 |
| renal distal | 2 |
| reactive oxygen | 2 |
| imaging manifestations | 2 |
| left lung | 2 |
| european society | 2 |
| cell cultures | 2 |
| invasive mv | 2 |
| polyacylamide gel | 2 |
| spacer region | 2 |
| low pathogenicity | 2 |
| factor ameliorates | 2 |
| therapeutic efficacy | 2 |
| type covid | 2 |
| renal injury | 2 |
| clinical findings | 2 |
| screening assay | 2 |
| local tissue | 2 |
| ace protein | 2 |
| essential role | 2 |
| proteolytic processing | 2 |
| serologic studies | 2 |
| consecutive negative | 2 |
| hplc study | 2 |
| two trained | 2 |
| organismal metabolic | 2 |
| transmission rate | 2 |
| metabolic activity | 2 |
| central china | 2 |
| serum glucose | 2 |
| fgf classes | 2 |
| macranthides hand | 2 |
| clinical aspects | 2 |
| high serum | 2 |
| liver diseases | 2 |
| appropriate use | 2 |
| preliminary study | 2 |
| sequence identity | 2 |
| ct values | 2 |
| lonicerae study | 2 |
| biomedicine literature | 2 |
| chinese biomedicine | 2 |
| icu stay | 2 |
| cov symptoms | 2 |
| mainly discussed | 2 |
| physiological level | 2 |
| medical supplies | 2 |
| beneficial effects | 2 |
| protecting healthcare | 2 |
| metabolic activities | 2 |
| children admitted | 2 |
| emerging human | 2 |
| isolation ward | 2 |
| medical care | 2 |
| colonic transit | 2 |
| rural areas | 2 |
| central register | 2 |
| muscle pain | 2 |
| pandemic potential | 2 |
| origin coronavirus | 2 |
| thereby contributing | 2 |
| coronavirus inhibition | 2 |
| disease severity | 2 |
| authorized users | 2 |
| probable cases | 2 |
| induced fibrogenesis | 2 |
| first evidence | 2 |
| inhibits macrophage | 2 |
| temperature reached | 2 |
| wasting disorders | 2 |
| randomized trial | 2 |
| new structural | 2 |
| first death | 2 |
| pneumonia emergency | 2 |
| acquired infections | 2 |
| syncytium formation | 2 |
| reported including | 2 |
| coronavirus hku | 2 |
| results suggested | 2 |
| wenzhou governance | 2 |
| macaque model | 2 |
| press conference | 2 |
| age years | 2 |
| significant threat | 2 |
| comparative experiments | 2 |
| factor levels | 2 |
| medicine shl | 2 |
| releasing factor | 2 |
| cardiac stress | 2 |
| short period | 2 |
| still many | 2 |
| illness associated | 2 |
| limited person | 2 |
| induced obesity | 2 |
| coronavirus mers | 2 |
| patients may | 2 |
| klebsiella pneumoniae | 2 |
| white lung | 2 |
| cellular receptor | 2 |
| cochrane central | 2 |
| modified vaccinia | 2 |
| metabolic functions | 2 |
| ruptured within | 2 |
| fingerprint atlas | 2 |
| fgf activates | 2 |
| immune function | 2 |
| pancreas secretagogue | 2 |
| helix bundle | 2 |
| polyproteins pp | 2 |
| endoplasmic reticulum | 2 |
| factor reduces | 2 |
| improves insulin | 2 |
| factor increases | 2 |
| see table | 2 |
| ct scans | 2 |
| peroxisome proliferatoractivated | 2 |
| induced pancreatitis | 2 |
| legal guardians | 2 |
| mv duration | 2 |
| predictive signs | 2 |
| widely recognized | 2 |
| biological specimens | 2 |
| primary cases | 2 |
| data extraction | 2 |
| including wat | 2 |
| replication cycle | 2 |
| later stages | 2 |
| five patients | 2 |
| control study | 2 |
| adhanom ghebreyesus | 2 |
| intercellular spaces | 2 |
| gastric bypass | 2 |
| tissue homeostasis | 2 |
| nasal mucosa | 2 |
| dependent rna | 2 |
| sympathetic nerve | 2 |
| study using | 2 |
| virus infection | 2 |
| acid tests | 2 |
| virus circulating | 2 |
| paracrine mode | 2 |
| potentially enhanced | 2 |
| postprandial serum | 2 |
| intermediate host | 2 |
| peribronchial lymphoid | 2 |
| china first | 2 |
| multiple hospitals | 2 |
| suspected case | 2 |
| daily necessity | 2 |
| superior quality | 2 |
| also known | 2 |
| specific primers | 2 |
| fgf exhibit | 2 |
| china national | 2 |
| china association | 2 |
| median age | 2 |
| two articles | 2 |
| germplasm resource | 2 |
| icu admission | 2 |
| prothrombin time | 2 |
| flos research | 2 |
| extremely high | 2 |
| sodium reabsorption | 2 |
| infection therapeutic | 2 |
| private hospital | 2 |
| documented exposure | 2 |
| positive qrt | 2 |
| good news | 2 |
| receiving corticosteroids | 2 |
| important roles | 2 |
| clinical update | 2 |
| quality among | 2 |
| like molecule | 2 |
| fgf analog | 2 |
| current treatment | 2 |
| active constituents | 2 |
| unanswered questions | 2 |
| candida glabrata | 2 |
| total body | 2 |
| time rt | 2 |
| novel viruses | 2 |
| diurnal bile | 2 |
| chen declare | 2 |
| latest advancements | 2 |
| hepatic fatty | 2 |
| cause damage | 2 |
| like symptoms | 2 |
| ventilation algorithm | 2 |
| data collection | 2 |
| high risk | 2 |
| bone fgf | 2 |
| healthcare system | 2 |
| scientific data | 2 |
| another report | 2 |
| specimens positive | 2 |
| pituitary gland | 2 |
| cardiovascular disease | 2 |
| support hubei | 2 |
| medical observation | 2 |
| coagulation function | 2 |
| drug development | 2 |
| chinese journal | 2 |
| another important | 2 |
| deep vein | 2 |
| factor gene | 2 |
| combating covid | 2 |
| direct contact | 2 |
| key point | 2 |
| fgf analogs | 2 |
| increased circulating | 2 |
| patients requiring | 2 |
| driven metabolic | 2 |
| coagulation disorders | 2 |
| false positive | 2 |
| syrian hamsters | 2 |
| critical illness | 2 |
| reverses hepatic | 2 |
| perforatus bat | 2 |
| brought back | 2 |
| pao fio | 2 |
| novel influenza | 2 |
| days apart | 2 |
| left ventricular | 2 |
| hormone fgf | 2 |
| multiple signal | 2 |
| genetic relationship | 2 |
| kinase domains | 2 |
| bilateral lung | 2 |
| mtor signaling | 2 |
| definition middle | 2 |
| staff using | 2 |
| plasma membrane | 2 |
| detected pathogen | 2 |